DSMB Greenlights Highest Dose Cohort for PepGen's DM1 Therapy, Data Readouts Set
PEPG sits 94% above its 52-week low of $1.01.
Summary
An independent safety board cleared PepGen to escalate its lead DM1 drug to the highest planned dose after reviewing data from the fully enrolled 10 mg/kg cohort. No serious safety signals emerged, and 6 of 8 patients from the lower dose opted into the extension study, signaling tolerability. The company now has a clear catalyst path: 10 mg/kg cohort results in November, followed by the 12.5 mg/kg data in the first half of 2027, with an OLE update by early January. This de-risks the program and sets up a potential end-of-Phase 2 meeting with regulators in 2027. With a $137M market cap and cash runway into H2 2027, positive data could materially change the company's valuation.
At the time of this announcement, PEPG was trading at $1.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $137M. The 52-week trading range was $1.01 to $7.80. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.